Drugs / GenSci120
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07040930 | Aug 2025 → Jul 2026 overdue | rheumatoid arthritis | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06827457 | Feb → Nov 2025 | autoimmune disease | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07423533 | Apr 2026 → Sep 2027 expected | rheumatoid arthritis | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06827457 ↗ |
| Route | Subcutaneous | “Single ascending doses of GenSci120 administered subcutaneously (SC).” NCT06827457 ↗ |